Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF EQUITY

v3.21.2
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Treasury
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance, shares (in shares) at Dec. 31, 2019     670,378,701 549,907        
Beginning balance at Dec. 31, 2019 $ 1,614,759 $ (1,342) $ 6,704 $ (1,791) $ 3,142,993 $ (22,070) $ (1,511,077) $ (1,342)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Equity-based compensation expense 4,037       4,037      
Net income (loss) (25,429)           (25,429)  
Other comprehensive income (loss) (3,682)         (3,682)    
Ending balance, shares (in shares) at Jun. 30, 2020     670,378,701 549,907        
Ending balance at Jun. 30, 2020 1,588,343   $ 6,704 $ (1,791) 3,147,030 (25,752) (1,537,848)  
Beginning balance, shares (in shares) at Mar. 31, 2020     670,378,701 549,907        
Beginning balance at Mar. 31, 2020 1,548,619   $ 6,704 $ (1,791) 3,145,444 (30,187) (1,571,551)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Equity-based compensation expense 1,586       1,586      
Net income (loss) 33,703           33,703  
Other comprehensive income (loss) 4,435         4,435    
Ending balance, shares (in shares) at Jun. 30, 2020     670,378,701 549,907        
Ending balance at Jun. 30, 2020 1,588,343   $ 6,704 $ (1,791) 3,147,030 (25,752) (1,537,848)  
Beginning balance, shares (in shares) at Dec. 31, 2020     670,585,576 549,907        
Beginning balance at Dec. 31, 2020 1,671,551   $ 6,706 $ (1,791) 3,152,694 (4,225) (1,481,833)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Equity-based compensation expense 6,107       6,107      
Exercise of Common Stock options and warrants (in shares)     181,125          
Exercise of Common Stock options and warrants 467   $ 2   465      
Conversion of 2025 convertible notes (in shares)     (19,051,270) (8,105,175)        
Conversion of 2025 convertible notes 55,275   $ 190   55,085      
Net income (loss) 14,892           14,892  
Other comprehensive income (loss) (5,707)         (5,707)    
Ending balance, shares (in shares) at Jun. 30, 2021     689,817,971 8,655,082        
Ending balance at Jun. 30, 2021 1,742,585   $ 6,898 $ (1,791) 3,214,351 (9,932) (1,466,941)  
Beginning balance, shares (in shares) at Mar. 31, 2021     670,703,076 549,907        
Beginning balance at Mar. 31, 2021 1,696,514   $ 6,707 $ (1,791) 3,155,648 (13,295) (1,450,755)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Equity-based compensation expense 3,460       3,460      
Exercise of Common Stock options and warrants (in shares)     63,625          
Exercise of Common Stock options and warrants 159   $ 1   158      
Conversion of 2025 convertible notes (in shares)     (19,051,270) (8,105,175)        
Conversion of 2025 convertible notes 55,275   $ 190   55,085      
Net income (loss) (16,186)           (16,186)  
Other comprehensive income (loss) 3,363         3,363    
Ending balance, shares (in shares) at Jun. 30, 2021     689,817,971 8,655,082        
Ending balance at Jun. 30, 2021 $ 1,742,585   $ 6,898 $ (1,791) $ 3,214,351 $ (9,932) $ (1,466,941)